CAR T-Cell Therapy

 

Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of CAR T cells.

A therapeutic CAR (chimeric antigen receptor) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signaling domains derived from the TCR g chain, along with other costimulatory receptors.  The scFv provides a specific binding domain that recognizes target proteins on cancer cells.  A patient’s own T cells are isolated and activated, then transfected with a gene expressing the CAR.  This reprograms the T cells to identify and attack tumor cells expressing the target protein, creating personalized immune cells designed to specifically target the patient’s cancer.

 The first FDA approved treatments were CAR T cells directed against the B cell protein CD19.  Success with CD19 has inspired new research identifying additional targets for several blood cancers and even solid tumors.  For example, early clinical trials using CAR-T treatment  suggest BCMA and CD22 are promising targets for multiple myeloma and acute lymphoblastic leukemia.  CD19-targeting CAR T cells are also in development as co-therapies with therapeutic antibodies targeting the PD-1:PD-L1 and CD28:CTLA4 pathways.  The aim of these early studies is to determine if CAR T cells can overcome the challenges of adaptive resistance to immune checkpoint therapies.

 At BPS Bioscience, we strive to provide tools at the cutting edge of cancer research. We produce a growing list of experimental cell lines, recombinant proteins, and screening services to advance the search for new CAR T cell therapies.  Contact us to find out how we can help with your research needs.

Items 26 to 45 of 45 total

per page
Page:
  1. 1
  2. 2

Catalog#SizeProduct NamePrice
72514 50 μg CD47, Fc Fusion, Avi-Tag, Biotin-Labeled (Mouse)
$435
71169 50 μg CD47, Fc fusion, Biotin-labeled (Human) HiP™
$435
71292 100 µg CD47, Fc-Fusion, Streptavidin-Labeled (Human) HiP™
$320
71127 100 µg CD47, His-tag (Human)
$325
79066 100 μg CD70, His-Tag (Mouse)
$325
40255 10 µg cMet, GST-tag
$355
40187 10 µg EGFR, His-tag, GST-tag
$355
100071 100 µg GPC3, Avi-His-Tagged
$320
79612 2 Vials HER2 (ERBB2) CHO Recombinant Cell Line (High, Medium, or Low Expression)
Starting at:
$6,000
40230 10 µg HER2, GST-tag
$355
71105

25 µg
50 µg
500 µg

PD-L1 (CD274), Fc fusion, Biotin-labeled (Human) HiP™
Starting at:
$360
71183

50 µg
500 µg

PD-L1 (CD274), FLAG-tag (Human) HiP™
Starting at:
$335
60543 2 vials PD-L1 - CHO Recombinant Cell Line
$4,125
71881 50 μg PD-L1, Fc Fusion (Human IgG1) PE-Labeled
$435
79641 2 Vials PSMA (FOLH1) - CHO Recombinant Cell Line (High, Medium, or Low Expression)
Starting at:
$6,000
79609 2 Vials ROR1 CHO Recombinant Cell Line
Starting at:
$5,500
79481 100 µg ROR1, Fc-Fusion (IgG1), Avi-Tag
$320
79482 50 µg ROR1, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$435
40396 10 µg ROR1, GST-tag
$390
79608 2 Vials SLAMF7 (CS1) CHO Recombinant Cell Line (High, Medium, or Low Expression)
Starting at:
$6,000

Items 26 to 45 of 45 total

per page
Page:
  1. 1
  2. 2